Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review.

Cancers (Basel) · 2024 · PMC11171072 · PMID 38893164

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although there was an improvement in overall survival and progression-free survival in the pembrolizumab group compared to the placebo, they did not reach statistical significance per the pre-specified trial criteria [ 43 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.